Traders bought shares of Bristol-Myers Squibb Co. (NYSE:BMY) on weakness during trading hours on Thursday. $163.17 million flowed into the stock on the tick-up and $119.18 million flowed out of the stock on the tick-down, for a money net flow of $43.99 million into the stock. Of all companies tracked, Bristol-Myers Squibb had the 32nd highest net in-flow for the day. Bristol-Myers Squibb traded down ($0.63) for the day and closed at $56.76

A number of analysts recently commented on BMY shares. Jefferies Group increased their price objective on Bristol-Myers Squibb from $77.00 to $80.00 and gave the company a “hold” rating in a research note on Thursday, July 14th. Berenberg Bank reaffirmed a “buy” rating on shares of Bristol-Myers Squibb in a research note on Tuesday, July 12th. Zacks Investment Research raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $85.00 price objective on the stock in a research note on Wednesday, July 13th. Vetr raised Bristol-Myers Squibb from a “sell” rating to a “buy” rating and set a $78.73 price objective on the stock in a research note on Monday, July 25th. Finally, SunTrust Banks Inc. lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $86.00 to $68.00 in a research note on Friday, August 5th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $72.12.

The stock has a market capitalization of $94.84 billion and a P/E ratio of 33.19. The company has a 50-day moving average of $66.60 and a 200 day moving average of $68.24.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, July 28th. The biopharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.66 by $0.03. The firm had revenue of $4.90 billion for the quarter, compared to the consensus estimate of $4.60 billion. Bristol-Myers Squibb’s revenue for the quarter was up 17.2% on a year-over-year basis. During the same quarter last year, the company posted $0.53 EPS. Equities research analysts expect that Bristol-Myers Squibb Co. will post $2.63 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, November 1st. Shareholders of record on Friday, October 7th will be issued a dividend of $0.38 per share. This represents a $1.52 dividend on an annualized basis and a yield of 2.68%. The ex-dividend date of this dividend is Wednesday, October 5th.

In other news, Director Lamberto Andreotti sold 23,200 shares of the firm’s stock in a transaction dated Friday, July 8th. The stock was sold at an average price of $74.45, for a total value of $1,727,240.00. Following the completion of the transaction, the director now owns 380,099 shares in the company, valued at approximately $28,298,370.55. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP John E. Elicker sold 11,820 shares of the firm’s stock in a transaction dated Tuesday, June 14th. The shares were sold at an average price of $72.69, for a total value of $859,195.80. Following the completion of the transaction, the senior vice president now owns 55,011 shares of the company’s stock, valued at approximately $3,998,749.59. The disclosure for this sale can be found here.

Several institutional investors recently made changes to their positions in the stock. Roosevelt Investment Group Inc. boosted its position in shares of Bristol-Myers Squibb by 78.7% in the fourth quarter. Roosevelt Investment Group Inc. now owns 423,373 shares of the biopharmaceutical company’s stock valued at $29,124,000 after buying an additional 186,514 shares during the last quarter. Cambridge Investment Research Advisors Inc. boosted its position in shares of Bristol-Myers Squibb by 6.7% in the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 150,480 shares of the biopharmaceutical company’s stock valued at $10,352,000 after buying an additional 9,500 shares during the last quarter. Argent Capital Management LLC boosted its position in shares of Bristol-Myers Squibb by 4.3% in the fourth quarter. Argent Capital Management LLC now owns 290,593 shares of the biopharmaceutical company’s stock valued at $19,990,000 after buying an additional 11,906 shares during the last quarter. St. Louis Trust Co bought a new position in shares of Bristol-Myers Squibb during the fourth quarter valued at $2,366,000. Finally, Jennison Associates LLC boosted its position in shares of Bristol-Myers Squibb by 19.2% in the fourth quarter. Jennison Associates LLC now owns 27,739,860 shares of the biopharmaceutical company’s stock valued at $1,908,225,000 after buying an additional 4,462,075 shares during the last quarter.

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.